Company: TELO
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-023970
Chunk: 45

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Item 8
Chunk 45
---
 zinc—that are associated
with oxidative stress, telomere shortening, and cellular aging. By modulating these ions, Telomir-1 is intended to support metal homeostasis,
reduce oxidative imbalance, and help preserve telomere integrity. This approach is based on emerging research indicating that metal ion
dysregulation can accelerate oxidative stress and contribute to cellular decline. Preclinical studies have shown that Telomir-1 may influence
pathways involved in telomere maintenance and cellular protection, supporting its potential as a therapeutic candidate for further development
in age-related conditions.

To
date, we have not generated any revenue nor do we expect to generate revenue unless and until we successfully complete preclinical and
clinical development of, receive regulatory approval for, and commercialize a program and we do not know when, or if at all, that will
occur. We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the preclinical
activities and studies and initiate clinical trials. In addition, if we obtain regulatory approval for any programs, we expect to incur
significant expenses related to production of sales, marketing, and distribution to the extent that such sales, marketing and distribution
are not the responsibility of potential collaborators. We expect to incur additional costs associated with operating as a public company.

We
had net losses of $5.1 million and $1.4 million for the three months ended June 30, 2025 and 2024, respectively and, $7.2 million and
$7.7 million for the six months ended June 30, 2025 and 2024, respectively.

Highlights-Three
Months Ended June 30, 2025

●
On May 15, 2025, we announced the identification of Telomir-Ag2 as a novel drug candidate following successful preclinical validation
of its antimicrobial activity. Telomir-Ag2 is a stabilized Silver(II) complex developed using the Company’s proprietary Telomir-1
platform.

●
On May 29, 2025, we announced new preclinical data from its ongoing development of Telomir-1, an investigational oral small molecule
candidate being developed for the treatment of age-related macular degeneration.

●
On June 5, 2025, we announced new data from a preclinical study of its lead compound, Telomir-1, in a validated animal model of Werner
Syndrome (WS